Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Işçimen A, Tüzün Y, Aktunç T, Pazarli H, Hamuryudan V, Müftüoğlu A
Department of Medicine, Cerrahpaşa Medical Faculty, University of Istanbul, Turkey.
Br J Ophthalmol. 1992 Apr;76(4):241-3. doi: 10.1136/bjo.76.4.241.
A single masked trial of cyclosporin A 5 mg/kg/day versus monthly 1 g intravenous boluses of cyclophosphamide was conducted among 23 patients with Behçet's syndrome and active, potentially reversible uveitis. The trial was unmasked after a mean of 12 (SD 2) months for the cyclosporin A group (n = 12) and a mean of 10 (SD 3) months for the cyclophosphamide group (n = 11). During the initial 6 months the visual acuity significantly improved (p < 0.001) in the cyclosporin A group whereas this was not observed in the cyclophosphamide group. The subsequent follow-up of patients up to 24 months suggested that the initial improvement in visual acuity with cyclosporin A was not sustained. More extensive and especially long-term studies of cyclosporin A in the uveitis of Behçet's syndrome are warranted.
对23例患有白塞氏综合征且伴有活动性、潜在可逆性葡萄膜炎的患者进行了一项单盲试验，比较每天5mg/kg的环孢素A与每月1g静脉注射大剂量环磷酰胺的疗效。环孢素A组（n = 12）平均12（标准差2）个月后试验揭盲，环磷酰胺组（n = 11）平均10（标准差3）个月后试验揭盲。在最初的6个月里，环孢素A组的视力显著改善（p < 0.001），而环磷酰胺组未观察到这种情况。随后对患者进行长达24个月的随访表明，环孢素A最初带来的视力改善并未持续。有必要对白塞氏综合征葡萄膜炎中环孢素A进行更广泛、尤其是长期的研究。
